Report
Johnson & Johnson in talks to buy eye-drug developer Ollin for up to $3.4 billion, FT reports
Terms under discussion include $2.2 billion upfront and $1.2 billion in potential milestone payments, the FT reports.
TLDR
The Financial Times reports that Johnson & Johnson could announce an Ollin Biosciences acquisition as soon as Monday, citing people familiar with the matter who cautioned that talks could still collapse. The deal would expand J&J’s limited presence in retinal disease medicines. Ollin’s lead drug, OLN324, is set for late-stage trials targeting two major causes of vision loss. Neither company immediately responded to the FT’s requests for comment.
Combined views
36K
2 Sources, first seen ago

Comments